Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Erik M. Schlicht"'
Autor:
Douglas I. Walker, Brian D. Juran, Angela C. Cheung, Erik M. Schlicht, Yongliang Liang, Megan Niedzwiecki, Nicholas F. LaRusso, Gregory J. Gores, Dean P. Jones, Gary W. Miller, Konstantinos N. Lazaridis
Publikováno v:
Hepatology Communications, Vol 6, Iss 5, Pp 965-979 (2022)
Progress in development of prognostic and therapeutic options for the rare cholestatic liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), is hampered by limited knowledge of their pathogeneses. In particular,
Externí odkaz:
https://doaj.org/article/71cdef31da544f249ec03b9bf014fede
Autor:
Ahmad Hassan Ali, Brian D. Juran, Erik M. Schlicht, Jackie K. Bianchi, Bryan M. McCauley, Elizabeth J. Atkinson, Konstantinos N. Lazaridis
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease that often progresses to end-stage liver disease and/or the development of hepatobiliary neoplasia. Lack of prognostic tools and treatment options f
Externí odkaz:
https://doaj.org/article/b7444afeb42948e8b5e6feb1df48ba6a
Autor:
Sohan Punia, Brian D. Juran, Ahmad H. Ali, Erik M. Schlicht, Raymond M. Moore, Zhifu Sun, Konstantinos N. Lazaridis
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Quantification of circulating organ-specific cell-free DNA (cfDNA) provides a sensitive measure of ongoing cell death that could benefit evaluation of the cholestatic liver diseases primary biliary cholangitis (PBC) and primary sc
Externí odkaz:
https://doaj.org/article/0f31c30141774d37ab2b7034806711db
Autor:
Angela C Cheung, Brian D Juran, Erik M Schlicht, Bryan M McCauley, Elizabeth J Atkinson, Raymond Moore, Julie K Heimbach, Kymberly D Watt, Tsung-Teh Wu, Nicholas F LaRusso, Gregory J Gores, Zhifu Sun, Konstantinos N Lazaridis
Publikováno v:
Epigenomics. 14:481-497
Aims: In this methylome-wide association study of cholestatic liver diseases (primary sclerosing cholangitis and primary biliary cholangitis), the authors aimed to elucidate changes in methylome and pathway enrichment to identify candidate genes. Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a72af1b9ef7ee1f5eb78294bc564493
https://doi.org/10.2217/epi-2021-0343
https://doi.org/10.2217/epi-2021-0343
Autor:
Caroline W Grant, Brian D Juran, Ahmad H Ali, Erik M Schlicht, Jackie K Bianchi, Xin Hu, Yongliang Liang, Zachery Jarrell, Ken H Liu, Young-Mi Go, Dean P Jones, Douglas I Walker, Gary W Miller, Trine Folseraas, Tom H Karlsen, Nicholas F LaRusso, Gregory J Gores, Arjun P Athreya, Konstantinos N Lazaridis
Publikováno v:
Exposome. 3
Primary sclerosing cholangitis (PSC) is a complex bile duct disorder. Its etiology is incompletely understood, but environmental chemicals likely contribute to risk. Patients with PSC have an altered bile metabolome, which may be influenced by enviro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a951de70950359caa06fe40bdc1e735d
https://doi.org/10.1093/exposome/osac011
https://doi.org/10.1093/exposome/osac011
Autor:
Douglas I. Walker, Yongliang Liang, Gregory J. Gores, Nicholas F. LaRusso, Megan M. Niedzwiecki, Brian D. Juran, Erik M. Schlicht, Dean P. Jones, Konstantinos N. Lazaridis, Angela C. Cheung, Gary W. Miller
Publikováno v:
Hepatology Communications. 6:965-979
Progress in development of prognostic and therapeutic options for the rare cholestatic liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), is hampered by limited knowledge of their pathogeneses. In particular,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd8eb231fb924e232973e303f59aeab
https://doi.org/10.1002/hep4.1871
https://doi.org/10.1002/hep4.1871
Autor:
Erik M. Schlicht, Konstantinos N. Lazaridis, Brian D. Juran, Ahmad H. Ali, Bryan M. McCauley, Jackie K. Bianchi, Elizabeth J. Atkinson
Background: Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease that often progresses to end-stage liver disease and/or the development of hepatobiliary neoplasia. Lack of prognostic tools and treatment options for PSC i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfce2ae7aa1761d06f58c116d5dece4a
https://doi.org/10.21203/rs.3.rs-629232/v1
https://doi.org/10.21203/rs.3.rs-629232/v1
Autor:
Erik M. Schlicht, Brian D. Juran, Bryan M. McCauley, Konstantinos N. Lazaridis, Ahmad H. Ali, Jackie K. Bianchi, Elizabeth J. Atkinson
Publikováno v:
BMC Gastroenterology
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-9 (2021)
Background Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease that often progresses to end-stage liver disease and/or the development of hepatobiliary neoplasia. Lack of prognostic tools and treatment options for PSC is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f5de19a21243eefc76ce1a56ad9d44e
https://pubmed.ncbi.nlm.nih.gov/34563121
https://pubmed.ncbi.nlm.nih.gov/34563121
Autor:
Gregory J. Gores, Bryan M. McCauley, Elizabeth J. Atkinson, Tom H. Karlsen, Konstantinos N. Lazaridis, Mette Vesterhus, Andrea A. Gossard, Erik M. Schlicht, John E. Eaton, Nicholas F. LaRusso, Brian D. Juran
Publikováno v:
Hepatology. 71:214-224
Improved methods are needed to risk stratify and predict outcomes in patients with primary sclerosing cholangitis (PSC). Therefore, we sought to derive and validate a prediction model and compare its performance to existing surrogate markers. The mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05bfc7b4fb780e42cdd66fa290a68594
https://doi.org/10.1002/hep.30085
https://doi.org/10.1002/hep.30085
Autor:
Brian D. Juran, Konstantinos N. Lazaridis, Sohan Punia, Erik M. Schlicht, Zhifu Sun, Ahmad H. Ali, Raymond Moore
Background: Quantification of circulating organ-specific cell-free DNA (cfDNA) provides a sensitive measure of ongoing cell death that could benefit evaluation of the cholestatic liver diseases primary biliary cholangitis (PBC) and primary sclerosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8f343685c738061169e130efae8b61e
https://doi.org/10.21203/rs.3.rs-209005/v1
https://doi.org/10.21203/rs.3.rs-209005/v1